← Back

09.01.2009
SBIR Phase 2 Renewal Funded

ioGenetics, LLC has received a three year Phase II Renewal Small Business Innovation Research grant to continue its work on development of immunotherapeutics for cryptosporidiosis. Following on its earlier Fast Track SBIR, this additional $3 million award will emphasize further development of products for control Cryptosporidium hominis. Antibody-fusion Directed Biocide™ products developed by ioGenetics will be tested at the University of Arizona in Tucson.